Safety of biologics in inflammatory bowel disease patients with COVID-19.

Simcha WeissmanMuhammad AzizWade-Lee SmithSameh EliasArun SwaminathJoseph D Feuerstein

Published in: International journal of colorectal disease (2021)

Our findings advocate for the continued biologic therapy in IBD patients during the COVID-19 pandemic. Nevertheless, the incidence, severity, and outcomes related to COVID-19 in IBD patients' needs to be reassessed as data continues to emerge.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
rheumatoid arthritis
sars cov
machine learning
adipose tissue
electronic health record
bone marrow
deep learning
mesenchymal stem cells
artificial intelligence